<DOC>
	<DOCNO>NCT01677910</DOCNO>
	<brief_summary>The primary objective study confirm least 1 dos telotristat etiprate compare placebo effective reduce number daily bowel movement ( BMs ) baseline average 12-week double-blind portion ( Treatment Period ) trial patient adequately control current SSA therapy .</brief_summary>
	<brief_title>TELESTAR ( Telotristat Etiprate Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Histopathologicallyconfirmed , welldifferentiated metastatic neuroendocrine tumor Documented history carcinoid syndrome currently experience ≥4 bowel movement per day Runin period Currently receive stabledose somatostatin analog ( SSA ) therapy Minimum dose LAR depot SSA therapy Octreotide LAR 30 mg every 4 week Lanreotide Depot 120 mg every 4 week Patients tolerate SSA therapy level indicate allow enter high tolerate dose Ability willingness provide write informed consent Presence diarrhea attribute condition ( ) carcinoid syndrome Karnofsky Performance status ≤60 % Treatment tumor direct therapy , include interferon , chemotherapy , mTOR inhibitor ≤4 week prior Screening , hepatic embolization , radiotherapy , radiolabelled SSA , and/or tumor debulking ≤12 week prior Screening History short bowel syndrome ( SBS ) Clinically significant cardiac arrhythmia , bradycardia , tachycardia would compromise patient safety outcome study , QTcF &gt; 450 m Previous exposure telotristat etiprate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>